FibroBiologics, Inc. Adjustments to Additional Paid in Capital, Other
FibroBiologics, Inc. (FBLG) reported Adjustments to Additional Paid in Capital, Other of $10.42 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2025-03-31
- FibroBiologics, Inc. adjustments to additional paid in capital, other for the quarter ending 2024-09-30 was $4.64M.
- FibroBiologics, Inc. adjustments to additional paid in capital, other for the quarter ending 2024-03-31 was $45.00K.
- FibroBiologics, Inc. adjustments to additional paid in capital, other for fiscal 2024 was $10.42M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|
| 2024-12-31 | $10.42M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $4.64M 10-Q · filed 2024-11-12 | |
| 2024-03-31 | $45.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |